Novo Nordisk has unveiled a multi-month subscription model for its weight-loss drug Wegovy, cementing the 'metabolic divide' as a permanent feature of modern healthcare. While the company frames these plans as 'removing barriers,' the reality is the creation of a tiered biological hierarchy. In the United States, patients are being pushed into long-term financial commitments to access high-dose treatments, while the Global South is flooded with $15 generics. This is the commodification of the human metabolism: your health is no longer a right, but a recurring revenue stream for pharmaceutical giants who have fenced off the very hormones that regulate our bodies.

This subscription-style pricing is designed to standardize profit, not wellness. By bypassing traditional insurance and marketing directly to the 'cash-paying' elite, Novo Nordisk is signaling the end of universal health standards. The Women’s Health AI Trap further complicates this, as algorithmic systems suppress information on female-specific conditions while facilitating the 'predatory impulse' of health-tech founders. When our biology is paywalled, we are no longer patients; we are assets being optimized for maximum yield. The enclosure of the body is complete when the ability to live a healthy life requires a monthly direct debit to a multinational corporation.